Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma
Noa Biran(Hackensack University Medical Center), David S. Siegel(Hackensack Meridian Health)
Cited by 9
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study
|PLoS ONE|2020|144